St. Jude Researchers and Collaborators Identified RBM5 as a Key Driver of Leukemia
oncodaily - St. Jude shared a post on X: “St. Jude researchers and collaborators identified RBM5 as a key driver of leukemia caused by changes in the KMT2A gene through its interaction with […]
AI Summary: St. Jude investigators report that RBM5 is a central driver in a form of childhood leukemia, revealing how the RNA-binding protein helps sustain malignant cells and interact with MYC pathways. The finding opens a plausible route to target an otherwise “undruggable” axis, offering a new precision strategy for high-risk pediatric leukemia.
Related Stories
Mass release of next‑generation tumor organoids accelerates research / 1 month
Some tumors kill neighboring healthy cells to fuel growth / 3 months
MYC overactivity enables DNA repair and chemotherapy resistance in tumours / 4 months
Enhertu (DESTINY‑Lung04) improves PFS in HER2‑mutant lung cancer / 6 wks
Engineered bacteria show promise as tumor‑targeting therapy in preclinical studies / 2 months
Daraxonrasib shows encouraging activity in NRAS-driven melanoma patients / 2 months
CAR‑T depletes mutant calreticulin cells, offering myelofibrosis hope / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Cancer Screening, Gene Therapy, Healthcare Finance, Obesity and look for the RSS link.
StackHealth Time Machine